Major Program
Supportive Care and Symptom Management
Research Group
Community Oncology and Prevention Trials
Sponsor
Donna Hammond, PhD
Status
Terminated
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT03642990
The purpose of this single-arm phase II trial is to determine whether nicotinamide riboside
(NIAGEN®) prevents the progression of peripheral sensory neuropathy in patients receiving
infusions of paclitaxel or nab-paclitaxel for the treatment of metastatic breast cancer or
recurrent platinum-resistant ovarian, endometrial, peritoneal, fallopian tube cancer or
metastatic head and neck cancer.
(NIAGEN®) prevents the progression of peripheral sensory neuropathy in patients receiving
infusions of paclitaxel or nab-paclitaxel for the treatment of metastatic breast cancer or
recurrent platinum-resistant ovarian, endometrial, peritoneal, fallopian tube cancer or
metastatic head and neck cancer.
Intervention
Nicotinamide Riboside
Condition
Chemotherapy-induced Peripheral Neuropathy, Breast Cancer Metastatic, Platinum-resistant Recurrent Ovarian Cancer, Head and Neck Cancer Stage IV, Endometrial Cancer Stage IV
Investigators
Donna L Hammond, PhD, Alexandra Thomas, MD